Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

Ketamine for OUD and Comorbid Depression (OUDCD)

A legfontosabb adatok

Ki végzi
University of Maryland, Baltimore
Hol
Baltimore (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
5 fő vett részt
Kezdés
2022. ápr. 4.
Befejezés
2023. nov. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ketamine Hydrochloride
A regiszteradat frissítve
2024. március 7.
Miért állt le
Study funds were exhausted

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • From NHS prescreen (no contact, Study Day 0): Between the ages of 18 to 65 years old
  • From NHS prescreen (no contact, Study Day 0): Daily use of illicit opioids
  • From NHS prescreen (no contact, Study Day 0): Fulfillment of DSM-5/ICD-10 criteria for moderate-to-severe opioid or heroin use disorder
  • From NHS prescreen (no contact, Study Day 0): Acceptance into methadone maintenance care for treatment of opioid or heroin use disorder
  • From screening for study eligibility (Study Contact Day 1): A total of 10 or more points on the PHQ-9
  • From screening for study eligibility (Study Contact Day 1): Have had no prior sustained experience/dependence on ketamine or PCP (i.e., must answer "no" to all four questions on the ketamine/PCP screen)

Ki nem vehet részt

  • From NHS prescreen (no contact, Study Day 0): Electrocardiogram (ECG) findings of tachycardia, prior myocardial infarction, myocardial ischemia, or aberrant conduction
  • From Psychiatric Evaluation (Study Contact Day 2) Current or previous recreational use of ketamine or PCP
  • From NHS prescreen (no contact, Study Day 0): Stage 2 hypertension, defined by a systolic blood pressure (SBP) > 140 mmHg or a diastolic blood pressure (DBP) > 90 mmHg
  • From NHS prescreen (no contact, Study Day 0): Any indication of serious mental illness or psychiatric disorder from the attending's evaluation notes
  • From Psychiatric Evaluation (Study Contact Day 2): Subjects who meet DSM-5 criteria for current bipolar disorder
  • From Psychiatric Evaluation (Study Contact Day 2): Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder
  • Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders
  • From NHS prescreen (no contact, Study Day 0): Clinically significant abnormal laboratory values, physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g., cardiovascular disease), as determined by the evaluating intake physician
  • From Liver Function Screen (Study Contact Day 2): Baseline alkaline phosphatase > 2.5 times the upper limit of normal
  • From NHS prescreen (no contact, Study Day 0): Patients transferring from another program of opioid agonist treatment
  • From NHS prescreen (no contact, Study Day 0): Self-report of recent prescribed or illicit benzodiazepine use ("Xannies", or "bars")
  • From NHS prescreen (no contact, Study Day 0): Urine screen positive for pregnancy
  • From NHS prescreen (no contact, Study Day 0): Any clinically significant abnormal findings from intake health and physical examination
  • From Liver Function Screen (Study Contact Day 2): Baseline aspartate aminotransferase > 3 times the upper limit of normal

Helyszínek itt: Egyesült Államok

  • University of Maryland, BaltimoreBaltimore, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Methadone is a first-line, evidence-based treatment for opioid use disorder (OUD). Unfortunately, retention and adherence in methadone treatment is a major challenge. OUD patients frequently present with co-morbid depression (OUDCD), a risk factor for poor OUD treatment outcomes, overdose, and suicide. The last two decades have seen an exciting and transformational development in the treatment of depression - ketamine. As a safe, rapid-acting anti-depressant deliverable within the context of methadone maintenance treatment, ketamine could feasibly change the landscape of treatment for OUD patients with comorbid depression. This proposal seeks to evaluate implementation outcomes (feasibility and patient acceptance) as well as preliminary efficacy of ketamine on methadone treatment outcomes for OUD patients (n=6) with comorbid depression and depressive symptoms presenting for methadone treatment.

A vizsgálat csoportja

  • KetamineA vizsgált kezelés

    Kezelés: Ketamine Hydrochloride

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)
Publikációk
A regiszteradat frissítve
2024. március 7.